Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Taro-Simvastatin · DIN 02265907 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2005-10-06 Health Canada: Cancelled post market since 2014-04-01 · brand TARO-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 40 MG · company Taro pharmaceuticals inc · schedule Prescription

DIN 02265907: Taro-Simvastatin Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240600032; group id 309; item number 0681; lccId None; manufacturer id TAR Source form: Tab; strength: 40mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02265907 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75135

Interchangeable products

AG-Simvastatin · DIN 02480085 · $0.2501 Apo-Simvastatin · DIN 02247014 · $0.2501 Auro-Simvastatin · DIN 02405172 · $0.2501 Co Simvastatin · DIN 02248106 · $0.2501 Jamp-Simvastatin · DIN 02375621 · $0.2501 Mar-Simvastatin · DIN 02375060 · $0.2501 Mint-Simvastatin · DIN 02372967 · $0.2501 PMSC-Simvastatin · DIN 02549662 · $0.2501 Pharma-Simvastatin · DIN 02470004 · $0.2501 Ran-Simvastatin · DIN 02329174 · $0.2501 Simvastatin · DIN 02284766 · $0.2501 Simvastatin · DIN 02386321 · $0.2501 Teva-Simvastatin · DIN 02250179 · $0.2501 Zocor · DIN 00884359 · $0.2501

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02265907

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2014-04-01 — choose a marketed DIN from the same-category list.